Haitron "Acquires $13.8 Million Worth of Shares in U.S. Subsidiary"
Haitron announced on the 5th that it will acquire 3,333,333 shares of Exicure, a U.S. nucleic acid therapeutic drug development company, for approximately 13.8 billion KRW.
After acquiring the shares, the ownership stake will be 60.5%. The scheduled date for the stock acquisition is the 14th.
Hot Picks Today
Wealth Surpasses 20 Quadrillion Won... The Super-Rich Score Big, But Where Did the Money Flow?
- "Just Drinking to Lift Your Mood"...Unexpected Warning: Raises Risk of Cancer Death
- [Report] AI Integrated into Suwon KT Wiz Park... From Entry to Cheering and Announcing in a Snap
- Is the "Batman Chicken Breast" Ukraine’s Lifeline Amid War? How It Broke Through the EU’s Strict Regulations [Delicious Stories]
- "What Is This Texture? It’s Totally My Style" Foreigners Fall in Love...‘Tteok’ Goes Viral on SNS [K-Holic]
Haitron stated that the purpose of this stock acquisition is a "paid-in capital increase for business expansion."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
